HLHong Li

Hong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Li has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors Associated With Successful In‐Office Diagnostic Vitreous Aspiration

    by Uyen Tu Nguyen, Joyce Kang, Hong Li, Kareem Moussa, Glenn Yiu

    Background and Objective: To identify demographic, clinical, and procedural factors associated with successful vitreous taps and aspirate volume to optimize candidate selection and technique for this procedure. Study Design/Patients and Methods: We performed a retrospective analysis of patients who underwent in‐office diagnostic vitreous aspiration from January 2010 to December 2022. We reviewed patient demographics, clinical characteristics, and procedural factors and then performed univariate and multivariable regression analyses to identify factors associated with successful vitreous tap and aspirate volume. Results: Among 101 eyes from 101 patients (64% aged 60 years or older, 37.6% female) who received diagnostic vitreous taps in clinic, 77.2% were successfully performed, while the remainder required aqueous sampling. Regression analyses showed that past vitrectomy ( p < 0.001) and smaller needle gauge ( p = 0.001) were associated with successful taps, where eyes with prior vitrectomy had a 100% success rate as compared to 68% in eyes without prior vitrectomy. Interestingly, larger 25‐gauge needles were less successful (68%) than 27‐gauge needles (93%), likely due to documentation of only the largest needle gauge attempted. Eyes that underwent successful vitreous aspiration had a mean aspirate volume of 0.3 ± 0.1 mL, with higher volumes observed in phakic than pseudophakic eyes (0.3 ± 0.1 vs. 0.2 ± 0.1 mL, p = 0.034), as well as those with suspected or actual diagnoses of endogenous versus exogenous infectious uveitis (0.4 vs. 0.2 mL, p = 0.002 and 0.4 vs. 0.2 mL, p = 0.003, respectively). Conclusion: In‐office diagnostic vitreous taps are more likely to be successful in vitrectomized eyes but do not appear to be affected by other factors such as the patient’s age, severity or type of intraocular inflammation, or larger needle gauge.

  • Open Access

    The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black women

    by Rachisan Djiake Tihagam, Song Lou, Yuanji Zhao, Kammi Song-Yan Liu, Arjun Tushir Singh, Bon Il Koo, Piotr Przanowski, Jie Li, Xiaosong Huang, Hong Li, et al.

    Triple-negative breast cancer (TNBC) disproportionately affects younger Black women, who show more aggressive phenotypes and poorer outcomes than women of other racial identities. While the impact of socioenvironmental inequities within and beyond health systems is well documented, the genetic influence in TNBC-associated racial disparities remains elusive. Here, we report that cancer-free breast tissue from Black women expresses TRIM37 at a significantly higher level relative to White women. A reporter-based screen for regulatory variants identifies a non-coding risk variant rs57141087 in the 5’ gene upstream region of the TRIM37 locus with enhancer activity. Mechanistically, rs57141087 increases enhancer–promoter interactions through NRF1, resulting in stronger TRIM37 promoter activity. Phenotypically, high TRIM37 levels drive neoplastic transformations in immortalized breast epithelial cells. Finally, context-dependent TRIM37 expression reveals that early-stage TRIM37 levels affect the initiation and trajectory of breast cancer progression. Together, our results indicate a genotype-informed association of oncogenic TRIM37 with TNBC risk in Black women and implicate TRIM37 as a predictive biomarker to better identify patients at risk of aggressive TNBC.


  • A Bayesian zero‐inflated beta‐binomial model for longitudinal data with group‐specific changepoints

    by Chun‐Che Wen, Nathaniel Baker, Rajib Paul, Elizabeth Hill, Kelly Hunt, Hong Li, Kevin Gray, Brian Neelon

    Timeline followback (TLFB) is often used in addiction research to monitor recent substance use, such as the number of abstinent days in the past week. TLFB data usually take the form of binomial counts that exhibit overdispersion and zero inflation. Motivated by a 12‐week randomized trial evaluating the efficacy of varenicline tartrate for smoking cessation among adolescents, we propose a Bayesian zero‐inflated beta‐binomial model for the analysis of longitudinal, bounded TLFB data. The model comprises a mixture of a point mass that accounts for zero inflation and a beta‐binomial distribution for the number of days abstinent in the past week. Because treatment effects appear to level off during the study, we introduce random changepoints for each study group to reflect group‐specific changes in treatment efficacy over time. The model also includes fixed and random effects that capture group‐ and subject‐level slopes before and after the changepoints. Using the model, we can accurately estimate the mean trend for each study group, test whether the groups experience changepoints simultaneously, and identify critical windows of treatment efficacy. For posterior computation, we propose an efficient Markov chain Monte Carlo algorithm that relies on easily sampled Gibbs and Metropolis–Hastings steps. Our application shows that the varenicline group has a short‐term positive effect on abstinence that tapers off after week 9.


  • Optimal Enrollment in Late-Stage New Drug Development with Learning of Drug’s Efficacy for Group-Sequential Clinical Trials

    by Zhili Tian, Gordon B. Hazen, Hong Li

    Problem definition: The cost for developing a new drug ranged from $1 billion to more than $2 billion between 2010 and 2019. In addition to high development costs, the efficacy of the candidate drug, patient enrollment, the market exclusivity period (MEP), and the planning horizon are uncertain. Moreover, slow enrollment leads to increased costs, canceled clinical trials, and lost potential revenue. Many firms, hoping to detect efficacy versus futility of the candidate drug early to save development costs, plan interim analyses of patient-response data in their clinical trials. Academic/practical relevance: The problem for optimizing patient-enrollment rates has an uncertain planning horizon. We developed a continuous-time dynamic programming (DP) model with learning of a drug’s efficacy and MEP to assist firms in developing optimal enrollment policies in their clinical trials. We also established the optimality equation for this DP model. Through a clinical trial for testing a cancer drug developed by a leading pharmaceutical firm, we demonstrate that our DP model can help firms effectively manage their trials with a sizable profit gain (as large as $270 million per drug). Firms can also use our model in simulation to select their trial design parameters (e.g., the sample sizes of interim analyses). Methodology: We update a drug’s efficacy by Bayes’ rules. Using the stochastic order and the likelihood-ratio order of distribution functions, we prove the monotonic properties of the value function and an optimal policy. Results: We established that the value of the drug-development project increases as the average response from patients using the candidate drug increases. For drugs having low annual revenue or a strong market brand or treating rare diseases, we also established that the optimal enrollment policy is monotonic in the average patient response. Moreover, the optimal enrollment rate increases as the variance of the MEP decreases. Managerial implications: Firms can use the properties of the value function to select late-stage clinical trials for their drug-development project portfolios. Firms can also use our optimal policy to guide patient recruitment in their clinical trials considering competition from other drugs in the marketplace. Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2022.1162 .


  • Efficacy of a brief telemedicine-based cognitive behavioral treatment (BRIGHT) versus attention control for head and neck cancer survivors with body image distress: A randomized trial.

    by Evan Michael Graboyes, Stacey N Maurer, Wendy Balliet, Hong Li, Amy M. Williams, Nosayaba Osazuwa-Peters, Lynne Padgett, Flora Yan, Tamar Gordis, Angie Rush, et al.

    212 Background: Nearly 1 in 3 head and neck cancer (HNC) survivors suffer from body image distress (BID), a source of devastating psychosocial morbidity that impairs quality of life. Evidence-based strategies to manage BID among HNC survivors are lacking. This trial evaluates the preliminary efficacy of BRIGHT (Building a Renewed ImaGe after Head & neck cancer Treatment), a brief tele-cognitive behavioral intervention, relative to attention control (AC), at reducing BID among HNC survivors. Methods: HNC survivors with clinically significant BID were randomized to BRIGHT (n = 20) or AC (n = 24). BRIGHT was delivered by a psychologist in 5 weekly video tele-medicine sessions. AC consisted of dose- and delivery-matched survivorship education. Changes in HNC-related BID and cancer-related BID were assessed using the IMAGE-HN and Body Image Scale (BIS), respectively. The effect of BRIGHT vs AC was analyzed using generalized linear models. Clinical response (proportion of patients with a clinically meaningful change in IMAGE-HN and BIS scores) for BRIGHT vs AC was analyzed with logistic regression. Results: The median age was 63 years (range 41-80) and 61% had stage III/IV HNC. BRIGHT decreased HNC-related BID from baseline to 1- and 3-months post-intervention relative to AC (Table). At 3-months post intervention, the response rate of BRIGHT on HNC-related BID was 6.6-fold higher than AC (OR = 6.6; 90% CI 2.0 to 21.8). BRIGHT decreased cancer-related BID from baseline to 3-months post-intervention vs AC (Table). The improvement in HNC-related BID and cancer-related BID for BRIGHT vs AC at 3-months was clinically significant and the effect size was large (Cohen’s d = -0.9, 90% CI -1.4 to -0.4 for each). Conclusions: In this pilot RCT, BRIGHT results in clinically meaningful improvements in BID among HNC survivors. These promising preliminary data support conducting a large efficacy trial to establish BRIGHT as the first evidence-based treatment for HNC survivors with BID. Clinical trial information: NCT03831100.

  • Open Access

    Plasticity in astrocyte subpopulations regulates heroin relapse

    by Anna Kruyer, Ariana Angelis, Constanza Garcia-Keller, Hong Li, Peter W. Kalivas

    Opioid use disorder (OUD) produces detrimental personal and societal consequences. Astrocytes are a major cell group in the brain that receives little attention in mediating OUD. We determined how astrocytes and the astroglial glutamate transporter, GLT-1, in the nucleus accumbens core adapt and contribute to heroin seeking in rats. Seeking heroin, but not sucrose, produced two transient forms of plasticity in different astroglial subpopulations. Increased morphological proximity to synapses occurred in one subpopulation and increased extrasynaptic GLT-1 expression in another. Augmented synapse proximity by astroglia occurred selectively at D2-dopamine receptor–expressing dendrites, while changes in GLT-1 were not neuron subtype specific. mRNA-targeted antisense inhibition of either morphological or GLT-1 plasticity promoted cue-induced heroin seeking. Thus, we show that heroin cues induce two distinct forms of transient plasticity in separate astroglial subpopulations that dampen heroin relapse.


  • Open Access

    Association between Neighborhood Social Deprivation and Stage at Diagnosis among Breast Cancer Patients in South Carolina

    by Oluwole Adeyemi Babatunde, Whitney E. Zahnd, Jan M. Eberth, Andrew B. Lawson, Swann Arp Adams, Eric Adjei Boakye, Melanie S. Jefferson, Caitlin G. Allen, John L. Pearce, Hong Li, et al.

    The purpose of this study was to examine the association between neighborhood social deprivation and individual-level characteristics on breast cancer staging in African American and white breast cancer patients. We established a retrospective cohort of patients with breast cancer diagnosed from 1996 to 2015 using the South Carolina Central Cancer Registry. We abstracted sociodemographic and clinical variables from the registry and linked these data to a county-level composite that captured neighborhood social conditions—the social deprivation index (SDI). Data were analyzed using chi-square tests, Student’s t-test, and multivariable ordinal regression analysis to evaluate associations. The study sample included 52,803 female patients with breast cancer. Results from the multivariable ordinal regression model demonstrate that higher SDI (OR = 1.06, 95% CI: 1.02–1.10), African American race (OR = 1.35, 95% CI: 1.29–1.41), and being unmarried (OR = 1.17, 95% CI: 1.13–1.22) were associated with a distant stage at diagnosis. Higher tumor grade, younger age, and more recent year of diagnosis were also associated with distant-stage diagnosis. As a proxy for neighborhood context, the SDI can be used by cancer registries and related population-based studies to identify geographic areas that could be prioritized for cancer prevention and control efforts.


  • A Bayesian hierarchical change point model with parameter constraints

    by Hong Li, Andreana Benitez, Brian Neelon

    Alzheimer’s disease is the leading cause of dementia among adults aged 65 or above. Alzheimer’s disease is characterized by a change point signaling a sudden and prolonged acceleration in cognitive decline. The timing of this change point is of clinical interest because it can be used to establish optimal treatment regimens and schedules. Here, we present a Bayesian hierarchical change point model with a parameter constraint to characterize the rate and timing of cognitive decline among Alzheimer’s disease patients. We allow each patient to have a unique random intercept, random slope before the change point, random change point time, and random slope after the change point. The difference in slope before and after a change point is constrained to be nonpositive, and its parameter space is partitioned into a null region (representing normal aging) and a rejection region (representing accelerated decline). Using the change point time, the estimated slope difference, and the threshold of the null region, we are able to (1) distinguish normal aging patients from those with accelerated cognitive decline, (2) characterize the rate and timing for patients experiencing cognitive decline, and (3) predict personalized risk of progression to dementia due to Alzheimer’s disease. We apply the approach to data from the Religious Orders Study, a national cohort study of aging Catholic nuns, priests, and lay brothers.


  • Statistical Methodology for Multiclass Classifications: Applications to Dementia

    by Hong Li, Sue Leurgans, Jordan Elm, Mulugeta Gebregziabher

    Alzheimer’s disease (AD) is a common, devastating disease which carries a heavy economic burden. Accelerated efforts to identify presymptomatic stages of AD and biomarkers to classify the disease are urgent needs. Currently no biomarkers can perfectl


  • Combining biomarker trajectories to improve diagnostic accuracy in prospective cohort studies with verification bias

    by Hong Li, Constantine Gatsonis

    In this paper, we develop methods to combine multiple biomarker trajectories into a composite diagnostic marker using functional data analysis (FDA) to achieve better diagnostic accuracy in monitoring disease recurrence in the setting of a prospective cohort study. In such studies, the disease status is usually verified only for patients with a positive test result in any biomarker and is missing in patients with negative test results in all biomarkers. Thus, the test result will affect disease verification, which leads to verification bias if the analysis is restricted only to the verified cases. We treat verification bias as a missing data problem. Under both missing at random (MAR) and missing not at random (MNAR) assumptions, we derive the optimal classification rules using the Neyman‐Pearson lemma based on the composite diagnostic marker. We estimate thresholds adjusted for verification bias to dichotomize patients as test positive or test negative, and we evaluate the diagnostic accuracy using the verification bias corrected area under the ROC curves (AUCs). We evaluate the performance and robustness of the FDA combination approach and assess the consistency of the approach through simulation studies. In addition, we perform a sensitivity analysis of the dependency between the verification process and disease status for the approach under the MNAR assumption. We apply the proposed method on data from the Religious Orders Study and from a non‐small cell lung cancer trial.